Lupin has signed a license and supply agreement with Sino Universal Pharmaceuticals (SUP), for the commercialization of Tiotropium Dry Powder Inhaler (DPI), 18 mcg/capsule, in the Chinese market, for the treatment of chronic obstructive pulmonary disease (COPD).
As per the agreement, SUP will obtain regulatory approvals for selling Tiotropium DPI in China, while Lupin will be the marketing authorization holder and responsible for manufacturing of the product.
Tiotropium DPI is known for its efficacy in improving lung function and quality of life for patients suffering from respiratory conditions. This partnership will enable Lupin to expand its footprint in China, ensuring that patients have timely access to innovative and high-quality healthcare solutions, considering the increasing prevalence of respiratory conditions.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
